

LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street
Vancouver, B.C., V6C 3B6



ANNOUNCEMENT OF PRIVATE PLACEMENT

December 4, 2017

SYMBOL – CSE - LLP

LeenLife Pharma International Inc. (“Company”) is pleased to announce a non-brokered private placement for gross proceeds of \$1,500,000. The non-brokered private placement, in accordance with rules of Canadian Securities Exchange, will consist of 15,000,000 units at \$0.10 per unit for total gross proceeds of \$1,500,000. Each unit will consist of one common share and one transferable share purchase warrant, each warrant exercisable into one additional common share at a price of \$0.15 per share for three years from closing.

All securities issued under the placement will be subject to statutory hold periods expiring four months and one day from issue date. Finders’ fee will be paid in cash at rates of up to 10%.

The proceeds of the private placement will be used for general working capital, purchase of a BioCube plant (see news release dated October 17, 2017) and expanding the company's presence and operations in Europe and North America.

About LeenLife

LeenLife has acquired a proprietary process to isolate omega-3 fatty acids from flax seeds. LeenLife products have been developed and researched for over 17 years. For additional information see our website at <http://leenlifepharma.com>.

For more information, please contact:

Stan Lis, CEO

Tel: 604 764-0518

E-mail: slis@leenlifepharma.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.